Assessment of Single‐Cycle M‐Protein Mutated Vesicular Stomatitis Virus as a Safe and Immunogenic Mucosal Vaccine Platform for SARS‐CoV‐2 Immunogen Delivery
2024

New Vaccine Platform for COVID-19 Using Mutated Virus

Sample size: 12 publication 10 minutes Evidence: moderate

Author Information

Author(s): Zhang En, Ke Yong, Ran Weihong, Zhang Yu, Li Ruihang, Fang Xinkui, Wang Lei, Zhang Baohong, Sun Tao

Primary Institution: Shanghai Jiao Tong University

Hypothesis

Can a single-cycle M-protein mutated vesicular stomatitis virus (VSVMT) serve as a safe and effective mucosal vaccine platform for delivering SARS-CoV-2 immunogens?

Conclusion

The study found that the VSVMT-S2P vaccine candidate is safe and can effectively stimulate immune responses in both healthy and immunocompromised animals.

Supporting Evidence

  • VSVMT-S2P was safe in both healthy and immunocompromised animals.
  • Single-cycle VSVMT-S2P induced significant antibody and T-cell responses.
  • Intramuscular administration of VSVMT-S2P produced neutralizing antibody responses comparable to those from replication-competent VSVMT-S.
  • Immunocompromised animals showed lower and delayed immune responses.

Takeaway

Researchers created a new vaccine using a modified virus that can help protect against COVID-19, and it seems safe for both healthy and sick animals.

Methodology

The study involved administering the VSVMT-S2P vaccine to hamsters and mice via intranasal and intramuscular routes, followed by monitoring immune responses and safety indicators.

Limitations

The immune responses in immunocompromised animals were lower and delayed compared to healthy animals.

Participant Demographics

Healthy and immunocompromised hamsters and Balb/c mice were used in the study.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1002/advs.202404197

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication